NCT00002173
Completed
Not Applicable
An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.
The Immune Response Corporation1 site in 1 countryAugust 31, 2001
ConditionsHIV Infections
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- HIV Infections
- Sponsor
- The Immune Response Corporation
- Locations
- 1
- Status
- Completed
- Last Updated
- 20 years ago
Overview
Brief Summary
To provide an alternative therapy to HIV-infected patients for whom there is no comparable or satisfactory alternative drug or therapy available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 4
Fosamprenavir Expanded AccessInfection, Human Immunodeficiency VirusNCT00240552ViiV Healthcare85
Available
Not Applicable
Expanded Access to TriheptanoinLong Chain Fatty Acid Oxidation DisordersNCT03773770Ultragenyx Pharmaceutical Inc
Completed
Not Applicable
An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/MlHIV InfectionsNCT00002172The Immune Response Corporation
Completed
Not Applicable
A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV InfectionHIV InfectionsNCT00002453Gilead Sciences300
Completed
Phase 3
A Study of Saquinavir Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected PatientsHIV InfectionsNCT00002382Hoffmann-La Roche4,000